Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MASP1 | SNV | Missense_Mutation | rs768033628 | c.2030G>A | p.Arg677His | p.R677H | P48740 | protein_coding | tolerated(0.27) | benign(0.019) | TCGA-A2-A0CO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
MASP1 | SNV | Missense_Mutation | | c.1484N>T | p.Ser495Leu | p.S495L | P48740 | protein_coding | tolerated(0.12) | benign(0.001) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MASP1 | SNV | Missense_Mutation | | c.1160C>G | p.Thr387Ser | p.T387S | P48740 | protein_coding | tolerated(0.05) | probably_damaging(0.977) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
MASP1 | SNV | Missense_Mutation | rs752301646 | c.1369G>A | p.Glu457Lys | p.E457K | P48740 | protein_coding | tolerated(0.84) | benign(0.036) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
MASP1 | SNV | Missense_Mutation | rs765808321 | c.1927G>A | p.Val643Ile | p.V643I | P48740 | protein_coding | tolerated(0.35) | benign(0.184) | TCGA-E2-A1IE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
MASP1 | SNV | Missense_Mutation | rs770101396 | c.1909N>T | p.Arg637Cys | p.R637C | P48740 | protein_coding | deleterious(0.01) | possibly_damaging(0.886) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD |
MASP1 | SNV | Missense_Mutation | rs767493716 | c.445N>A | p.Glu149Lys | p.E149K | P48740 | protein_coding | deleterious(0.04) | possibly_damaging(0.815) | TCGA-4J-AA1J-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MASP1 | SNV | Missense_Mutation | rs751292648 | c.1465N>A | p.Ala489Thr | p.A489T | P48740 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MASP1 | SNV | Missense_Mutation | novel | c.1885N>A | p.Glu629Lys | p.E629K | P48740 | protein_coding | tolerated(0.27) | benign(0.036) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
MASP1 | SNV | Missense_Mutation | novel | c.409G>A | p.Ala137Thr | p.A137T | P48740 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-VS-A9UL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |